MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a study finds.

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Confira a cotação BIIB hoje e acompanhe as ações Biogen em tempo real. As seções dessa página permitem ver o preço da ação agora, comparar com dados históricos, ver gráficos, dividendos e indicadores ...

Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.